FME FRESENIUS MEDICAL CARE AG

DGAP-News: Fresenius Medical Care published form 20-F for the fiscal year 2019

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous
Fresenius Medical Care published form 20-F for the fiscal year 2019

21.02.2020 / 11:54
The issuer is solely responsible for the content of this announcement.



Fresenius Medical Care, the world's largest provider of dialysis products and services, has filed the annual report 2019 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors" section as well as at the SEC's website ().

A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at .

The company also published a Facts & Figures 2019 website at to provide an overview of the key financial figures for the fiscal year 2019. In addition, the new Corporate Magazine, Company Profile as well as a Five-Year-Summary are available for download.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at and .

Disclaimers
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.




 


21.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail:
Internet:
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID: 980927

 
End of News DGAP News Service

980927  21.02.2020 

fncls.ssp?fn=show_t_gif&application_id=980927&application_name=news&site_id=research_pool
EN
21/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FRESENIUS MEDICAL CARE AG

Fresenius Medical Care AG - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Carole Braudeau
  • Carole Braudeau

Credit Morning 11/18/2025

Celanese: CFR downgraded by S&P, with the outlook still negative|Eroski announces refinancing plan including new offering of 2031 notes|Altice International: exclusive talks for the sale of Hot Mobile for NIS 2.1bn (€ 561m)|Crédit Agricole S.A. unveils its strategic plan ACT 2028|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 18/11/2025

Celanese: CFR downgraded by S&P, with the outlook still negative|Eroski annonce un plan de refinancement comportant une nouvelle émission obligataire 2031|Altice International : négociations exclusives pour la vente de Hot Mobile pour 2,1 mds NIS (561 m EUR)|Crédit Agricole présente ce matin son nouveau plan stratégique 2028|

Carole Braudeau
  • Carole Braudeau

Credit Morning 11/04/2025

Webuild: CFR upgraded by S&P to BB+|ELO a achevé la mise en autonomie financière d’Auchan Retail et de NIH et a bénéficié du soutien de l’AFM à hauteur de 425 m EUR|Picard: new SUNs offering due 2032 and tender offer on the existing SUNs due 2027|

ResearchPool Subscriptions

Get the most out of your insights

Get in touch